USP

Ramipril

Name: Ramipril
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Tritace, [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid

Slide 1 of 1

Select a Size

Pricing and availability is not currently available.

About This Item

Empirical Formula (Hill Notation):

C₂₃H₃₂N₂O₅

CAS Number:

87333-19-5

Molecular Weight:

416.51

MDL number:

MFCD00865775

UNSPSC Code:

41116107

PubChem Substance ID:

329751020

NACRES:

NA.24

Key Documents

View All Documentation

grade

pharmaceutical primary standard

API family

ramipril

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C(N1[C@](CCC2)([H])[C@]2([H])C[C@H]1C(O)=O)[C@H](C)N[C@H](C(OCC)=O)CCC3=CC=CC=C3

InChI

1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1

InChI key

HDACQVRGBOVJII-JBDAPHQKSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	R0145000	BP751	R0404
USP 1598303 Ramipril	R0145000 Ramipril	BP751 Ramipril	Sigma-Aldrich R0404 Ramipril
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade -
manufacturer/tradename USP	manufacturer/tradename EDQM	manufacturer/tradename BP	manufacturer/tradename -
format neat	format neat	format neat	format -
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical pharmaceutical small molecule	application(s) -
API family ramipril	API family ramipril	API family ramipril	API family -
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Angiotensin converting enzyme (ACE) inhibitor.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1598314

Ramipril Related Compound A, United States Pharmacopeia (USP) Reference Standard

1598347

Ramipril Related Compound D, United States Pharmacopeia (USP) Reference Standard

R0145000

Ramipril, European Pharmacopoeia (EP) Reference Standard

R0145005

Ramipril impurity A, European Pharmacopoeia (EP) Reference Standard

R0145020

Ramipril impurity D, European Pharmacopoeia (EP) Reference Standard

R0145010

Ramipril impurity B, European Pharmacopoeia (EP) Reference Standard

R0145015

Ramipril impurity C, European Pharmacopoeia (EP) Reference Standard

1598323

Ramipril Related Compound B, United States Pharmacopeia (USP) Reference Standard

1598338

Ramipril Related Compound C, United States Pharmacopeia (USP) Reference Standard

BP751

Ramipril, British Pharmacopoeia (BP) Reference Standard

BP754

Ramipril impurity K, British Pharmacopoeia (BP) Reference Standard

Pictograms

GHS08

Signal Word

Danger

Hazard Statements

H360FD

Precautionary Statements

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].

W Linz et al.

Zeitschrift fur Kardiologie, 83 Suppl 4, 53-56 (1994-01-01)

ACE inhibitors induce an increase in kinin levels with subsequent release of nitric oxide (NO) and prostacyclin, as shown in cultured endothelial cells and isolated rat hearts. Isolated perfused working rat hearts continuously release kinins and prostacyclin. During ischemia after

Ramipril-induced liver injury: case report and review of the literature.

Antonios Douros et al.

American journal of hypertension, 26(9), 1070-1075 (2013-06-12)

Ramipril, an inhibitor of the angiotensin-converting enzyme (ACEI), is a drug commonly used in the therapy of hypertension. ACEI-induced hepatotoxicity is rare, and most of the reported cases are associated with captopril. Here, we present the first case of ramipril-induced

Ramipril: a review of its use in the prevention of cardiovascular outcomes.

Gregory T Warner et al.

Drugs, 62(9), 1381-1405 (2002-06-22)

Ramipril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which is rapidly hydrolysed after absorption to the active metabolite ramiprilat. Earlier trials have shown that ACE inhibitors, when given to patients with low ejection fractions, have reduced the relative risk

Ramipril in the treatment of vascular diseases.

Michael J Rokoss et al.

Expert opinion on pharmacotherapy, 6(11), 1911-1919 (2005-09-08)

Ramipril is an angiotensin-converting enzyme inhibitor that has been extensively studied in randomised, controlled clinical trials in patients with cardiovascular diseases. Therapy with ramipril in patients with various cardiovascular disorders has demonstrated significant and clinically important reductions in cardiovascular death

Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients.

Carolina De Ciuceis et al.

Hypertension (Dallas, Tex. : 1979), 64(4), 717-724 (2014-07-02)

Structural alterations of subcutaneous small-resistance arteries are associated with a worse clinical prognosis in hypertension and non-insulin-dependent diabetes mellitus. The effects of the direct renin inhibitor aliskiren on microvascular structure were never previously evaluated. Therefore, we investigated the effects of

View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service